NHL All-Star Ryan Getzlaf Joins Forces with Global Nonprofit to Help Find a Cure for Duchenne Muscular Dystrophy NEWPORT BEACH, Calif., (September 20, 2022) – CureDuchenne, a leading global nonprofit […]
Dr. Paolo Bettica will review recently completed study analysis for the Italfarmaco Phase 3 randomized controlled trial of givinostat in boys with Duchenne muscular dystrophy (DMD). He will answer your […]
The “What?”, “When?” and “How?” that everyone is asking. This webinar will leave you with a better understanding of the different types of treatments and cures for Duchenne that are […]
Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today positive 4-month interim results […]
An interview with the Millers and Ryan Getzlaf discussing the Getzlaf Golf Shootout that originally aired on NBC4
– Initiation of LYNX Phase 2 clinical trial in individuals with DMD expected in Q4 2022 – Boulder, Colo., (September 7, 2022) – Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage […]
As an early funder of Dyne Therapeutics, CureDuchenne is pleased to share that Dyne has dosed the first participant in their clinical trial in Duchenne amenable to skipping exon 51.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on SRP-5051 […]
Published program data shows Dyne’s FORCE™ platform achieves enhanced exon skipping and prolonged dystrophin restoration in Duchenne in vivo mdx mouse model CureDuchenne provided funding to Dyne Therapeutics and we […]
